STOCK TITAN

Vanguard disaggregates holdings after Jan 12, 2026 realignment; reports 0 shares in Chemours (CC)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Chemours Co/The — The Vanguard Group filed Amendment No. 11 to its Schedule 13G/A reporting beneficial ownership of 0 shares (0%) of Chemours common stock. The filing states that an internal realignment effective January 12, 2026 caused certain Vanguard subsidiaries/divisions to report holdings separately in reliance on SEC Release No. 34-39538.

The filing is signed by Ashley Grim, Head of Global Fund Administration on 03/26/2026 and lists Vanguard's principal business office in Malvern, Pennsylvania.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/26/2026

FAQ

What does Vanguard report for Chemours (CC) ownership in this amendment?

The filing reports 0 shares (0%) of Chemours common stock. This amendment states Vanguard holds no sole or shared voting or dispositive power over Chemours shares as reported.

Why are Vanguard subsidiaries reporting separately for Chemours (CC)?

Vanguard undertook an internal realignment effective January 12, 2026, and in reliance on SEC Release No. 34-39538, certain subsidiaries/divisions now report beneficial ownership separately from The Vanguard Group, Inc.

Who signed the Schedule 13G/A amendment for Vanguard on Chemours (CC)?

Ashley Grim, Head of Global Fund Administration, signed the amendment on 03/26/2026. The filing includes Vanguard's Malvern, Pennsylvania business address.

Does this amendment show any Vanguard voting or dispositive power for Chemours (CC)?

No; the amendment lists 0 for sole and shared voting power and 0 for sole and shared dispositive power. Vanguard reports no beneficial ownership in the class in this filing.

Is the 0-share report for Chemours (CC) tied to a change in reporting method?

Yes; the 0-share position follows Vanguard's reporting change after the January 12, 2026 realignment, where subsidiaries that formerly reported together now report on a disaggregated basis per SEC guidance.
Chemours Co

NYSE:CC

View CC Stock Overview

CC Rankings

CC Latest News

CC Latest SEC Filings

CC Stock Data

3.12B
149.68M
Specialty Chemicals
Chemicals & Allied Products
Link
United States
WILMINGTON